clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Achlorhydria D000126 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Eye Infections D015817 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Myxoma D009232 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Serositis D012700 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Discitis D015299 2 associated lipids
Iris Diseases D007499 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Fractures, Open D005597 3 associated lipids
Barrett Esophagus D001471 3 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Confusion D003221 4 associated lipids
Prurigo D011536 4 associated lipids
Lymphangitis D008205 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Mycetoma D008271 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Duodenitis D004382 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Foot Diseases D005534 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ergotism D004881 4 associated lipids
Cysts D003560 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Dyspepsia D004415 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Formanoy E et al. Tenosynovitis of the right hand. Mycobacterium kansasii. 2013 Neth J Med pmid:24394739
Patel AM et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. 2013 Ann. Intern. Med. pmid:23778904
Morakul B et al. Precipitation-lyophilization-homogenization (PLH) for preparation of clarithromycin nanocrystals: influencing factors on physicochemical properties and stability. 2013 Int J Pharm pmid:24076396
Siamas K and Khachemoune A Mycobacteria infection in an immunocompetent patient with no risk factors: evaluation and management of non-healing majocchi granuloma-type nodule. 2013 Dermatol. Online J. pmid:24021439
Xu Y et al. Synthesis and antibacterial activity of novel modified 5-O-mycaminose 14-membered ketolides. 2013 Eur J Med Chem pmid:24021890
Ranganathan D et al. Mycobacterium fortuitum peritonitis in a patient receiving continuous ambulatory peritoneal dialysis. 2013 Saudi J Kidney Dis Transpl pmid:24029271
Krashias G et al. Prevalence of Helicobacter pylori cagA and vacA genes in Cypriot patients. 2013 J Infect Dev Ctries pmid:24042099
Nguyen L and Taylor-Gjevre RM An emerging role for clarithromycin in adult-onset still disease? 2013 J Clin Rheumatol pmid:24048102
Trespalacios AA et al. Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia. 2013 J. Microbiol. pmid:23990295
Lee YC et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. 2013 Gut pmid:22698649
Saviola G et al. Clarithromycin in rheumatoid arthritis: the addition to methotrexate and low-dose methylprednisolone induces a significant additive value--a 24-month single-blind pilot study. 2013 Rheumatol. Int. pmid:23864141
Amado-Rodríguez L et al. Anti-inflammatory effects of clarithromycin in ventilator-induced lung injury. 2013 Respir. Res. pmid:23663489
Pereira JM et al. Interplay of degradation, dissolution and stabilization of clarithromycin and its amorphous solid dispersions. 2013 Mol. Pharm. pmid:24116899
Huang J et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. 2013 Aliment. Pharmacol. Ther. pmid:24117692
Yoon H et al. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? 2013 J. Gastroenterol. Hepatol. pmid:24118110
Chen K et al. Low dose macrolide administration for long term is effective for otitis media with effusion in children. 2013 Auris Nasus Larynx pmid:22673738
Drago F et al. Acute autoimmune thrombocytopenia and worsening of dermatomyositis after administration of clarithromycin. 2013 J. Am. Acad. Dermatol. pmid:24124859
Wang S et al. A supra-monolayer nanopattern for organic nanoparticle array deposition. 2013 ACS Appl Mater Interfaces pmid:23480527
Nykula TD and Furleta VV [Rationale for improved treatment of ulcerative disease complicated by chronic pyelonephritis]. 2013 Lik. Sprava pmid:25095689
Raghunatha K and George JP Periodontal tissue and serum concentration of clarithromycin after systemic administration in patients affected by chronic periodontitis. 2013 J. Periodontol. pmid:23451987
Liang X et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. 2013 Clin. Gastroenterol. Hepatol. pmid:23376004
Calza P et al. Fate of selected pharmaceuticals in river waters. 2013 Environ Sci Pollut Res Int pmid:22851223
Morse AL et al. A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North. 2013 Can. J. Gastroenterol. pmid:24340314
Mikamo H et al. [Infection and host reaction]. 2013 Jpn J Antibiot pmid:24649796
Zhen-Hua Z et al. Characterization of 23S rRNA gene mutation in primary and secondary clarithromycin-resistant Helicobacter pylori strains from East China. 2013 Turk J Gastroenterol pmid:23794337
Evdokimova AG et al. [New approaches to therapy of Helicobacterpylori infection (by the materials of the Maastricht Consensus-IV, Florence, 2010)]. 2013 Antibiot. Khimioter. pmid:24640139
Onal IK et al. What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study. 2013 Clin Res Hepatol Gastroenterol pmid:23796974
de Zeeuw J et al. Serum levels of neopterin during antimicrobial treatment for Mycobacterium ulcerans infection. 2013 Am. J. Trop. Med. Hyg. pmid:23836576
Janković B et al. Consolidation trend design based on Young's modulus of clarithromycin single crystals. 2013 Int J Pharm pmid:23872226
Shinahara W et al. Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. 2013 PLoS ONE pmid:23875018
Friedman ND et al. Mycobacterium ulcerans disease: experience with primary oral medical therapy in an Australian cohort. 2013 PLoS Negl Trop Dis pmid:23875050
Suzuki RB et al. Low Helicobacter pylori primary resistance to clarithromycin in gastric biopsy specimens from dyspeptic patients of a city in the interior of São Paulo, Brazil. 2013 BMC Gastroenterol pmid:24305035
Yano K et al. Clinical outcome of the chronic flexor tenosynovitis in the hand caused by non-tuberculous mycobacterium treated by extensive tenosynovectomy and drugs. 2013 J Plast Surg Hand Surg pmid:23875916
Trifan A et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. 2013 World J. Gastroenterol. pmid:24259981
Laving A et al. Effectiveness of sequential v. standard triple therapy for treatment of Helicobacter pylori infection in children in Nairobi, Kenya. 2013 S. Afr. Med. J. pmid:24300630
Venerito M et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. 2013 Digestion pmid:23880479
Cecchini MP et al. Might Helicobacter pylori infection be associated with distortion on taste perception? 2013 Med. Hypotheses pmid:23845559
Delgado JS et al. Granulomatous gastritis and Helicobacter pylori infection. 2013 Isr. Med. Assoc. J. pmid:23882902
Lee HJ et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. 2013 J. Infect. Dis. pmid:23801607
Shallom SJ et al. New rapid scheme for distinguishing the subspecies of the Mycobacterium abscessus group and identifying Mycobacterium massiliense isolates with inducible clarithromycin resistance. 2013 J. Clin. Microbiol. pmid:23804391
Kim SG et al. [Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. 2013 Korean J Gastroenterol pmid:23954956
Yoshida S et al. Further isolation of Mycobacterium abscessus subsp. abscessus and subsp. bolletii in different regions of Japan and susceptibility of these isolates to antimicrobial agents. 2013 Int. J. Antimicrob. Agents pmid:23850022
Dib J et al. Efficacy of PPI, levofloxacin and amoxicillin in the eradication of Helicobacter pylori compared to conventional triple therapy at a Venezuelan hospital. 2013 Arab J Gastroenterol pmid:24206741
Gibbins NE et al. Time to reconsider guidelines on clarithromycin in chronic rhinosinusitis? 2013 BMJ pmid:23635541
Pilcer G et al. Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis. 2013 Int J Pharm pmid:23643509
Rimbara E et al. Helicobacter cinaedi and Helicobacter fennelliae transmission in a hospital from 2008 to 2012. 2013 J. Clin. Microbiol. pmid:23658263
Bismuth + metronidazole + tetracycline. Why risk adding bismuth? 2013 Prescrire Int pmid:23662315
Zhuo FL et al. Clinical isolates of Mycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility. 2013 Chin. Med. J. pmid:23673103
Seck A et al. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. 2013 Ann. Clin. Microbiol. Antimicrob. pmid:23298145
Rossi A et al. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. 2013 Blood pmid:23299315
Andersen JT et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. 2013 PLoS ONE pmid:23301061
Kwak HM et al. The efficacy of cefazolin plus macrolide (erythromycin or clarithromycin) versus cefazolin alone in neonatal morbidity and placental inflammation for women with preterm premature rupture of membranes. 2013 Placenta pmid:23465535
Huang HC et al. Primary central nervous system diffuse large B cell lymphoma transformed from orbital mucosa-associated lymphoid tissue lymphoma: complete response to combined intrathecal and systemic rituximab. 2013 Ann. Hematol. pmid:23242476
Ang TL et al. Is there still a role for empiric first-line triple therapy using proton pump inhibitor, amoxicillin and clarithromycin for Helicobacter pylori infection in Singapore? Results of a time trend analysis. 2013 J Dig Dis pmid:23253473
Danilko L et al. [Clarithromycin therapy of a B cell MALT lymphoma]. 2013 Ophthalmologe pmid:23224128
Singh RP et al. Antimicrobial prophylaxis in open reduction and internal fixation of compound mandibular fractures: a collaborative regional audit of outcome. 2013 Br J Oral Maxillofac Surg pmid:23369782
Prasertpetmanee S et al. Improved efficacy of proton pump inhibitor - amoxicillin - clarithromycin triple therapy for Helicobacter pylori eradication in low clarithromycin resistance areas or for tailored therapy. 2013 Helicobacter pmid:23356886
Nakamura Y et al. Optimal duration of macrolide treatment for chronic sinusitis after endoscopic sinus surgery. 2013 Auris Nasus Larynx pmid:23107100
Kazama I and Maruyama Y Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes. 2013 Pharm Biol pmid:23527897
Kawai Y et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients. 2013 Antimicrob. Agents Chemother. pmid:23459497
Sardarian H et al. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. 2013 Helicobacter pmid:23121338
Liou JM et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. 2013 Lancet pmid:23158886
Sarkeshikian SS et al. Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. 2013 Turk J Gastroenterol pmid:23794338
Uthman MM et al. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV. 2013 Cochrane Database Syst Rev pmid:23633339
Kupcinskas L et al. Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania. 2013 APMIS pmid:23078193
Wu Y et al. Overexpression of YKL-40 predicts plaque instability in carotid atherosclerosis with CagA-positive Helicobacter pylori infection. 2013 PLoS ONE pmid:23573226
Koh WJ et al. Reply: drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions. 2013 Am. J. Respir. Crit. Care Med. pmid:23577353
Schmitt BH et al. PCR detection of clarithromycin-susceptible and -resistant Helicobacter pylori from formalin-fixed, paraffin-embedded gastric biopsies. 2013 Mod. Pathol. pmid:23579617
Lai J et al. Epithelioid histiocytic infiltrate caused by Mycobacterium scrofulaceum infection: a potential mimic of various neoplastic entities. 2013 Am J Dermatopathol pmid:22935892
Boyanova L et al. Living in Sofia is associated with a risk for antibiotic resistance in Helicobacter pylori: a Bulgarian study. 2013 Folia Microbiol. (Praha) pmid:23580173
Bradbeer L et al. Childhood headache and H. pylori--a possible association. 2013 Aust Fam Physician pmid:23529524
Yula E et al. Detection of primary clarithromycin resistance of Helicobacter pylori and association between cagA (+) status and clinical outcome. 2013 Folia Microbiol. (Praha) pmid:22956464
Zhou L et al. Cutaneous Mycobacterium intracellulare infection in an immuno-competent person. 2013 Acta Derm. Venereol. pmid:23532357
Marin AC et al. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). 2013 Expert Opin Pharmacother pmid:23537368
Phunpruch S et al. A role for 16S rRNA dimethyltransferase (ksgA) in intrinsic clarithromycin resistance in Mycobacterium tuberculosis. 2013 Int. J. Antimicrob. Agents pmid:23541074
Alhajlan M et al. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. 2013 Antimicrob. Agents Chemother. pmid:23545534
Goh IX et al. Cytochrome P450 drug interactions with statin therapy. 2013 Singapore Med J pmid:23546024
Georgopoulos S et al. Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial. 2013 J. Clin. Gastroenterol. pmid:22858517
Malfertheiner P [Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance]. 2013 Dtsch. Med. Wochenschr. pmid:23512360
Seneviratne K and Herieka E A rifampicin-resistant Mycobacterium marinum infection in a newly diagnosed HIV-1 individual. 2013 Int J STD AIDS pmid:23512514
Liu MK et al. Randomized trial comparing rabeprazole- versus lansoprazole-based Helicobacter pylori eradication regimens. 2013 Kaohsiung J. Med. Sci. pmid:23768702
Li XM et al. Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials. 2013 Chin. Med. J. pmid:23769580
Asaoka D et al. Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area. 2013 Helicobacter pmid:23773231
Al-Haj A et al. Method development, validation and bioequivalence of varenicline in human plasma by liquid chromatography tandem mass spectrometry. 2013 J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. pmid:23774248
Quinney SK et al. Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin. 2013 Eur. J. Clin. Pharmacol. pmid:22777148
Kim T et al. [Clarithromycin-resistant Helicobacter pylori associated with 23S rRNA point mutations in Jeju Island]. 2013 Korean J Gastroenterol pmid:23756666
Howard ST Recent progress towards understanding genetic variation in the Mycobacterium abscessus complex. 2013 Tuberculosis (Edinb) pmid:24388643
Georgopoulos SD et al. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. 2013 Helicobacter pmid:23714140
Koh WJ et al. Successful treatment of Mycobacterium massiliense lung disease with oral antibiotics only. 2013 Antimicrob. Agents Chemother. pmid:23183432
Cerqueira RM et al. Cumulative Helicobacter pylori eradication therapy in obese patients undergoing gastric bypass surgery. 2013 Obes Surg pmid:23054570
Zendedel A et al. Antibiotic resistance of Helicobacter pylori in Mashhad, Iran. 2013 J Pak Med Assoc pmid:23914633
Maggi P et al. Fatal fulminant hepatitis following administration of clarithromycin in a patient chronically treated with antipsycotic drugs. 2013 Immunopharmacol Immunotoxicol pmid:22804484
Haider M et al. Post-operative sinus formation due to Mycobacterium abscessus: a case report. 2013 Indian J Tuberc pmid:24000496
Hong SK et al. First case of Mycobacterium longobardum infection. 2013 Ann Lab Med pmid:24003427
Labenz J [Fewer stomach cancers after Helicobacter pylori eradication]. 2013 MMW Fortschr Med pmid:24006589
Miyauchi R et al. Clarithromycin-induced haemorrhagic colitis. 2013 BMJ Case Rep pmid:23964038
Gandhi S et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. 2013 JAMA pmid:24346990
Nagaoka K et al. Macrolides inhibit Fusobacterium nucleatum-induced MUC5AC production in human airway epithelial cells. 2013 Antimicrob. Agents Chemother. pmid:23380724
Moriya S et al. Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. 2013 Int. J. Oncol. pmid:23546223
Akiyoshi T et al. Mechanism-based inhibition profiles of erythromycin and clarithromycin with cytochrome P450 3A4 genetic variants. 2013 Drug Metab. Pharmacokinet. pmid:23514827